About Us

Our Vision

Our vision is to redefine the future of healthcare by providing innovative, effective, and accessible treatments for severe inflammation. We are committed to improving the quality of life for patients worldwide, fostering a future where no one has to live with the debilitating effects of severe inflammation.

Our Mission

Our mission is to bring RG210179, a patented first-in-class Aquaporin-9 inhibitor for the treatment of acute pancreatitis into a clinical development program.

Our History

ApoGlyx was founded in 2015 based on ten years of research by CEO Dr. Michael Rützler and Prof. Dr. Med. Søren Nielsen, at Aarhus University, together with the group of Prof. Per Kjellbom from Lund University that led to the discovery of small molecule aquaporin-9 inhibitors. Our company was founded by passionate inventors to tackle metabolic diseases involving the regulation of glycerol uptake into the liver, but as research and development proceeded our scope has widened due to the potential of this technology in further applications.

Research in Søren Nielsen’s group had previously demonstrated normalization of blood glucose in otherwise type-2 diabetic mice if the aquaporin-9 gene was missing. This observation led to the hypothesis that chemical inhibition of aquaporin-9 could be suitable to treat human type-2 diabetes. It was then when the academic researchers started to collaborate with Red Glead Discovery, to explore the possibility of optimizing early lead aquaporin-9 inhibitors, and to further validate aquaporin-9, as a drug target in type-2 diabetes.


Subsequent exploratory work was supported by grants from the Novo Nordisk Foundation and Vinnova, as part of the SWElife projects for better health programme and in collaboration with the group of Prof. Giuseppe Calamita at the University of Bari, Italy. This work has led to two proof-of-concept demonstrations in in vivo disease models, utilizing the lead aquaporin-9 inhibitor RG100204:

1) A blood glucose lowering effect the in an
in vivo model of diabetes (1).
2) A strong protection from organ damage
has been demonstrated in a clinically
relevant in vivo model of sepsis (2).

  1. Florio, M., Engfors, A., Gena, P., Larsson, J., Massaro, A., Timpka, S. et al. (2022) Characterization of the Aquaporin-9 Inhibitor RG100204 In Vitro and in db/db Mice Cells 11, 10.3390/cells11193118
  2. Mohammad, S., O'Riordan, C. E., Verra, C., Aimaretti, E., Alves, G. F., Dreisch, K. et al. (2022) RG100204, A Novel Aquaporin-9 Inhibitor, Reduces Septic Cardiomyopathy and Multiple Organ Failure in Murine Sepsis Front Immunol 13, 900906 10.3389/fimmu.2022.900906


Michael Rützler, PhD

Read More

Preben Bruun-Nyzell

Read More

Helen Petterson, PhD

Read More

Johan Evenäs, PhD

Read More

Lars Grundemar, MD, PhD

Read More

Andreas L. Norlin, PhD

Read More


The ApoGlyx scientific advisory board exists to:

  • Help shape the development program and product portfolio
  • Serve as objective reviewers who have an external perspective and are a mark of quality and authentication

Professor Søren Nielsen, MD

Read More

Professor John Dirk Nieland, PhD

Read More

Professor Giuseppe Calamita, PhD

Read More


ApoGlyx is collaborating with the groups of Professor Giuseppe Calamita at the University of Bari, Professor Angela Tesse Ragot at the University of Nantes, France, and the group of Professor Per Kjellbom at Lund University, to further elucidate the function and mode of action of aquaporin-9 in sepsis, diabetes and non-alcoholic fatty liver disease. The collaboration recently included exchange, and joint supervision of students, joint international grant applications, and has resulted in joint publications.